Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 8. In vivo suppression of MM by CMLD

Published bySuparman Hartanto Modified over 6 years ago

Similar presentations

Presentation on theme: "Fig. 8. In vivo suppression of MM by CMLD"— Presentation transcript:

1 Fig. 8. In vivo suppression of MM by CMLD010509.
In vivo suppression of MM by CMLD (A) Diagram of in vivo studies performed. SCID mice were injected with MM1S GFP (green fluorescent protein)/Luc+. After engraftment, the mice were randomized to two groups based on BLI, and CMLD or vehicle control was administered by intraperitoneal (i.p.) injections at 0.7 mg/kg two times a week. Tumor growth was assessed by weekly bioluminescence (BLI) counts, (B) showing a significant difference in tumor growth between the DMSO-treated group and the CMLD group; P < (C) Kaplan-Meier curve showing a significant survival difference between vehicle- and drug-treated mice, with a median OS of 35 versus 47 days, P < (D) Immunohistochemistry for CD138, Ki-67, and MYC in bone marrow samples from the KMS-11–injected mice. Scale bars, 50 μm. (E) Electrophoresis of serum proteins from transplantable Vk*Myc mice indicating the presence of a γ-globulin (M-spike) in the DMSO control group (arrow) at 4 weeks. C57BL/6 syngeneic mice were intravenously injected with 3.5 × 106 Vk*Myc cells. At day 7 after tumor cells injection, mice were randomized into two groups and received DMSO (n = 10) or CMLD drug (n = 10, 0.7 mg/kg per mouse) through intraperitoneal injections twice a week. (F) Kaplan-Meier curve showing a significant survival difference between vehicle- and drug-treated mice, with a median OS of 39 days versus not reached, P = Statistical analyses were performed using log-rank test. Salomon Manier et al., Sci Transl Med 2017;9:eaal2668 Published by AAAS

Download ppt "Fig. 8. In vivo suppression of MM by CMLD"

Similar presentations

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy by Marta Chesi, Geoffrey M. Matthews, Victoria.

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy by Marta Chesi, Geoffrey M. Matthews, Victoria.
Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging by Matthias Edinger, Yu-An Cao, Michael R. Verneris,

Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging by Matthias Edinger, Yu-An Cao, Michael R. Verneris,
Fig. 3. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis and survival. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis.

Fig. 3. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis and survival. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis.
Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 5 Maraba induces antitumor T cell immunity.
Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.

Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.
In vivo prophylactic and therapeutic efficacy of C12G6 in mice

In vivo prophylactic and therapeutic efficacy of C12G6 in mice
Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.
In vivo responses of AMLMLL to ATRi.

In vivo responses of AMLMLL to ATRi.
Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.
Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade
Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.
Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.
Fig. 8. Therapeutic effects of the transplantation of hiPSC-EPO–producing cells on renal anemia in adenine-treated mice. Therapeutic effects of the transplantation.

Fig. 8. Therapeutic effects of the transplantation of hiPSC-EPO–producing cells on renal anemia in adenine-treated mice. Therapeutic effects of the transplantation.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Similar presentations

Ads by Google